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Background:  Little  has  been  known  about  clinical  features  and  prognosis  of  very  old  patients  with
heart failure  with  preserved  ejection  fraction  (HFPEF).  The  aim  of  this  study  was  to  compare
clinical  features  and  clinical  outcomes  between  HFPEF  and  heart  failure  with  reduced  ejection
fraction (HFREF)  in  patients  older  than  80  years.
Methods:  We  enrolled  a  total  of  113  patients  over  80  years  old,  who  were  admitted  for  heart
failure between  2006  and  2009.  We  retrospectively  analyzed  the  clinical  features  including
laboratory  data  and  echocardiography  parameters.
Results:  In  53  patients  (49%)  left  ventricular  ejection  fraction  was  preserved.  The  clinical  char-
acteristics  and  treatment  between  HFPEF  and  HFREF  showed  that  anemia  was  one  of  the  risk
factors for  HFPEF,  and  the  long-term  outcomes  of  HFPEF  in  this  population  were  not  different
from that  of  HFREF.
Conclusion:  These  results  suggest  that  anemia  is  one  of  the  important  risk  factors  for  HFPEF  in
the very  elderly.
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eart  failure  is  a common  problem  in  elderly  people.  In
he  elderly  population,  heart  failure  with  preserved  ejection
raction  (HFPEF)  has  been  increasingly  recognized.  Previous
eports  suggested  that  the  rate  of  HFPEF  was  up  to  30—50%
Published by Elsevier Ltd. All rights reserved.


















































Over  80  years old (n=128)
EF confirmed by
echoca rdiography (n=113)
Echocardiography not availa ble (n=9)
Moderate to severe MR, Aorti c stenosis, 
Constricti ve Pericarditi s (n=6)
HFPEF(n=55) HFREF(n=58 )
CHF admi ssions in 2006 -2009( n=511)
EF 50% EF<50%
Figure  1  Flow  chart  of  patient  selection.  CHF,  chronic  heart

































f  all  patients  with  heart  failure  and  the  rate  of  HFPEF
ncreases  according  to  age  [1,2]. HFPEF  is  accompanied  by
ypertension,  diabetes  mellitus,  and  atrial  ﬁbrillation,  while
eart  failure  with  reduced  ejection  fraction  (HFREF)  is  often
ccompanied  by  ischemic  heart  disease  and  dilated  car-
iomyopathy  [3—6]. However  little  is  known  about  clinical
eatures  and  prognosis  of  HEPEF  in  very  old  patients.  More-
ver,  it  is  not  known  whether  the  long-term  outcome  with
FPEF  is  different  from  that  with  HFREF  in  very  elderly  peo-
le.  The  aim  of  this  study  was  to  compare  clinical  features
nd  clinical  outcomes  between  HFPEF  and  HFREF  in  patients
lder  than  80  years.
ethods
atient  population
etween  2006  and  2009,  there  were  511  patients  admitted
or  the  treatment  of  heart  failure  in  our  hospital.  The  def-
nition  of  heart  failure  followed  the  Framingham  criteria.
mong  these  511  patients,  we  included  patients  over  80
ears  old  whose  echocardiography  was  available  and  EF  was
onﬁrmed  by  echocardiography.
Eligible  patients  were  those  hospitalized  for  worsen-
ng  heart  failure  as  the  primary  cause  of  admission.  For
ach  patient,  baseline  data  obtained  at  discharge  included
he  following  demographic  parameters:  cause  of  heart
ailure,  precipitating  cause,  comorbidities,  complications,
linical  status,  electrocardiographic  and  echocardiographic
ndings,  plasma  brain-type  natriuretic  peptide  (BNP),  and
reatment  including  discharge  medications.  Heart  failure
ue  to  acute  myocardial  infarction  was  excluded.  Heart  fail-
re  due  to  valve  heart  disease  such  as  mitral  regurgitation
r  constrictive  pericarditis  was  not  excluded.
atients  and  follow-up
e  retrospectively  analyzed  the  clinical  features  including
aboratory  data  and  echocardiography  parameters.  Follow-
p  was  performed  via  last  ofﬁce  visit  of  medical  records.
eﬁnition  of  other  clinical  criteria
eﬁnitions  of  the  clinical  criteria  were  deﬁned  as  follows:
ypertension,  systolic  blood  pressure  >140  mmHg  or  dias-
olic  blood  pressure  >90  mmHg,  or  medical  treatment  for
ypertension  before  admission;  hyperlipidemia,  cholesterol
evel  >220  mg/dl  or  treatment  for  hyperlipidemia  before
dmission;  diabetes  mellitus,  hemoglobin  A1c  level  >6.5%
r  treatment  for  diabetes  mellitus  before  admission.  Ane-
ia  was  deﬁned  as  hemoglobin  concentration  (<12  g/dl  in
ales  or  <11  g/dl  in  females)  [7].  The  presence  of  atrial  ﬁb-
illation,  and  the  background  disease  or  etiology  of  heart
ailure,  were  examined  from  the  medical  records.  The  med-
cation  data  were  adopted  at  the  time  of  ﬁrst  discharge.
stimated  glomerular  ﬁltration  rate  (eGFR)  was  calculated








ieart failure  with  preserved  ejection  fraction;  HFREF,  heart
ailure  with  reduced  ejection  fraction.
chocardiography
chocardiography  was  obtained  by  using  commercially  avail-
ble  ultrasound  systems  (SSA-380A,  Toshiba,  Tokyo,  Japan  or
ONOS-7500,  Phillips,  Atlanta,  GA,  USA).  EF  was  calculated
y  Teichholz  method.  Echocardiography  was  performed
ithin  one  week  from  hospital  admission.  HFPEF  was  deﬁned
s  EF  ≥50%  and  HFREF  as  EF  <50%.
tatistical  analysis
ata  are  presented  as  frequencies  for  categorical  variables
nd  mean  ±  SD  for  continuous  variables.  Data  were  analyzed
ith  t-test  or  Mann—Whitney  U-test.  Categorical  data  were
ompared  using  Fisher’s  exact  test.  Log-rank  testing  was
sed  to  analyze  signiﬁcant  differences  in  adverse  events
etween  the  two  groups.  A  p-value  <0.05  was  considered
o  indicate  statistical  signiﬁcance.  All  analyses  were  per-
ormed  using  statistical  software,  SPSS  13.0/Windows  (SPSS
nc.,  Chicago,  IL,  USA).
esults
here  were  511  patients  who  were  admitted  to  our  hospital
or  the  treatment  of  chronic  heart  failure  (CHF)  between
006  and  2009  (Fig.  1).  Among  511  patients,  128  patients
ere  over  80  years  old.  In  these  128  patients,  15  patients
12%)  had  moderate-to-severe  mitral  regurgitation  or  aor-
ic  stenosis  and  constrictive  pericarditis  and  they  were
xcluded.  The  remaining  113  patients  whose  echocardiogra-
hy  was  available  and  EF  was  conﬁrmed  by  echocardiography
ere  analyzed  in  this  study.  Among  these  113  patients,
here  were  55  with  HFPEF  (49%)  and  58  with  HFREF  (51%)
Fig.  1).
Table  1  shows  the  clinical  characteristics  and  medication
f  the  two  groups.  Ischemic  heart  disease  (IHD)  as  back-
round  disease  was  more  frequent  in  HFREF.  The  level  of
NP  was  signiﬁcantly  higher  in  HFREF  than  HFPEF.  Calcium-
hannel  blockers  were  more  frequently  prescribed  in  HFPEF.
eft  ventricle  wall  was  thicker  in  HFPEF.  The  level  of
emoglobin  was  lower  in  HFPEF  than  HFREF.  Anemia  was
ore  frequent  in  HFPEF.  The  results  of  logistic  multivariate
nalysis  for  the  parameters  which  were  signiﬁcant  (p  <  0.05)
n  multivariate  analysis  (IHD,  calcium-channel  blocker,  BNP,
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Table  1  Clinical  features  of  chronic  heart  failure.
Variables HFPEF  (n  =  55)  HFREF  (n  =  58)  p-Value
Age,  year  84.30  ±  3.92  83.97  ±  3.80  0.73
Gender, male  22(40%)  24(41%)  0.40
Body mass  index  (kg/m2)  21.0  ±  3.65  21.1  ±  3.23  0.86
Hypertension  39(71%)  32(55%)  0.12
Dyslipidemia 11(20%)  11(19%)  1.00
Diabetes mellitus 14(25%)  17(29%)  0.68
Atrial ﬁbrillation 22(40%)  28(48%)  0.45
Ischemic heart  diseases 14(25%)  27(47%)  0.03
Renin-angiotensin  system  inhibitors  36(65%)  39(67%)  0.70
-Blockers 26(47%)  28(48%)  1.00
Calcium-channel  blockers  24(44%)  9(16%)  <0.01
Diuretics 48(87%)  54(93%)  0.23
Creatinine (ml/min)  1.29  ±  1.05  1.25  ±  0.69  0.17
Sodium (meqiv./l)  139.40  ±  5.10  140.55  ±  3.87  0.33
Hemoglobin  (g/dl)  10.91  ±  2.06  11.68  ±  1.64  0.04
Anemia 32(58%)  23(42%)  0.03
Brain natriuretic  peptide  (pg/dl)  620.21  ±  442.39  1014.11  ±  736.99  <0.01
Ejection fraction  (%)  60.40  ±  8.57  34.59  ±  9.05  <0.01
Dd (mm) 47.5  ±  6.9  57.2  ±  9.7  <0.01
Ds (mm)  32.1  ±  6.3  47.3  ±  10.4  <0.01
IVST (mm) 11.3  ±  2.8  9.8  ±  2.2  <0.01
PWT (mm)  10.2  ±  1.7  9.2  ±  1.7  <0.01
Left ventricular  mass  index  (g) 164.9  ±  81.7  167.9  ±  104.7  0.26
E/A 0.79 ±  0.23  1.05  ±  0.60  0.39
e′ (cm/s)  3.73  ±  1.10  2.99  ±  1.09  0.20
E/e′ 7.22  ±  5.02  11.74  ±  8.69  0.19
Total death  of  any  cause 8(15%)  6(10%)  0.28
Mean ± SD, number (%).











dsystolic dimension; IVST, intraventricular septum thickness; PWT, 
and  anemia)  showed  that  anemia  was  independently  asso-
ciated  with  HFPEF  in  the  elderly  (p  =  0.02,  odds  ratio  =  3.11,
95%  conﬁdence  interval:  01.24—7.80)  (Table  2).
The  Kaplan—Meyer  curves  of  all-cause  death,  cardio-
vascular  death,  and  heart  failure-related  re-hospitalization
between  HFPEF  and  HFREF  are  shown  in  Fig.  2.  The  mean
follow-up  period  was  266  ±  358  days  (mean  ±  SD).  There  was
no  difference  in  all-cause  mortality,  cardiovascular  death,
and  heart  failure-related  re-hospitalization  between  HFPEF
and  HFREF.Discussion
Our  study  has  showed  that  the  49%  of  CHF  cases  in  the





Table  2  Logistic  multivariate  analysis  of  risk  factors  for  heart  fai
Ischemic  heart  disease  
Calcium-channel  blockers  
Brain natriuretic  peptide  (per  +100-pg/ml  increase)  
Anemia rior wall thickness.
ith HFPEF.  The  all-cause  death,  cardiovascular  death,  and
e-hospitalization  were  not  different  between  HFPEF  and
FREF  in  the  very  elderly.
Previous  reports  showed  that  the  frequency  of  HFPEF
as  30—50%  among  CHF  in  overall-age  population  [1—3,5]
ncreasing  with  age  [9].  This  study  showed  that  49%  of  CHF
atients  in  the  elderly  were  HFPEF,  which  is  in  line  with
he  previous  studies.  Age  [6,10], female  gender  [5,6,10],
ypertension  [1,6,10—12], diabetes  mellitus  [3,6], atrial  ﬁb-
illation  [3,6], use  of  calcium-channel  blockers  [13,14]  or
igoxin,  and  left  ventricular  hypertrophy  [5],  are  reported
o  be  associated  with  HFPEF.  IHD  [4],  dyslipidemia,  statin
se  [13], and  a  higher  level  of  hemoglobin  [13]  are  also
eported  to  be  associated  with  HFREF.  In  our  study  with  the
ery  elderly  patients,  calcium-channel  blockers  were  more
lure  with  preserved  ejection  fraction  in  the  elderly.
Odds  ratio  95%  CI  p-Value
0.23  0.11—0.73  0.01
2.43  0.94—6.30  0.07
1.14  1.04—1.28  <0.01
3.11  1.24—7.80  0.02
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Figure  2  (a)  Survival  free  from  all-cause  death.  (b)  Survival  free  from  cardiac  death.  (c)  Survival  free  from  heart  failure-related

































Study limitationsraction; HFREF,  heart  failure  with  reduced  ejection  fraction.
requently  prescribed,  and  left  ventricular  hypertrophy  was
ore  often  observed  in  HFPEF,  which  was  in  agreement  with
revious  reports  on  HEPEF  [3,5,13,15]. In  our  study,  the  fre-
uencies  of  female  sex,  hypertension,  diabetes  mellitus,
trial  ﬁbrillation,  are  not  signiﬁcantly  different  between
FPEF  and  HFPRF.
Anemia  has  been  reported  as  a  risk  factor  for  HFPEF  in
 previous  report  [16], which  was  also  consistent  with  this
resent  study.  Aging  is  a  strong  determinant  of  prognosis,
nd  prevalence  of  other  systemic  diseases  such  as  malig-
ancy  or  renal  dysfunction  increase  with  age  [17]. Renal
ysfunction  also  might  lead  to  the  decreased  production
f  endogenous  erythropoietin  and  might  ultimately  induce
nemia.  In  our  study,  however,  the  renal  function  was  not
igniﬁcantly  different  between  HFPEF  and  HFREF.  A  previous
tudy  reports  that  the  frequency  of  malignancy  was  signif-
cantly  higher  in  HFPEF  than  HFREF  [14]. The  existence  of
alignancy  may  have  to  be  sought  in  cases  with  HFPEF  in
he  elderly  population  especially  in  anemic  patients.  In  this
F
setrospective  analysis,  the  cause  of  anemia  was  not  deter-
ined.
There  are  conﬂicting  reports  regarding  the  long-term
utcomes  of  HFPEF.  Some  have  shown  similar  event  rates
etween  HFPEF  or  HFREF  [1,5,13],  while  others  have  shown
etter  event  rates  in  HFPEF  [2,3,18].  In  our  study  on  the
ery  elderly,  the  all-cause  death,  cardiac  death,  and  heart
ailure-related  re-hospitalization  were  not  signiﬁcantly  dif-
erent  between  the  two  groups.  However,  a  large  number
f  non-cardiac  deaths  such  as  malignant  tumor,  pneumonia,
nd  stroke  can  confound  the  results  in  the  elderly  popula-
ion.  Our  results  suggest  that  the  prognosis  of  HFPEF  was  as
oor  as  HFREF  in  the  very  elderly;  however,  this  should  be
onﬁrmed  in  a  larger  population.irst,  a  retrospective  study  design  with  a  relatively  small
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selection  bias.  Second,  documentation  of  biochemistry  data
at  hospital  discharge  might  not  accurately  reﬂect  the  level
after  discharge  or  changes  over  time.  Third,  echocardiogra-
phy  data  were  obtained  by  the  Teicholz  method,  which  may
not  accurately  reﬂect  the  actual  EF  in  some  patients.
Conclusions
Our  study  has  shown  that  nearly  half  of  the  CHF  patients
over  80  years  of  age  had  HFPEF.  Anemia  was  one  of  the  risk
factors  for  HFPEF,  and  the  long-term  outcomes  of  HFPEF  in
this  population  were  not  different  from  that  of  HFREF.
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